Clinical trials: Osteoporosis, Postmenopausal
Osteoporosis
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
- Trial name
- NCT06504966
- Testing
- MAB-22, Prolia®
- Sponsor
- Xentria, Inc.
Osteoporosis, Postmenopausal, Osteoporosis
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk
- Trial name
- NCT03710889
- Testing
- Abaloparatide
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Radius Health, Inc.
Osteoporosis, Post-Menopausal
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
- Trial name
- NCT00532246
- Testing
- raloxifene
- Where
- 5 sites in United States
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Osteoporosis With Pathological Fracture
Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo
The primary objective of this study is to compare efficacy and safety of two formulations of teriparatide 20 mcg/day plus calcium and vitamin D in postmenopausal women with osteoporosis.
- Trial name
- NCT01945788
- Testing
- Teriparatide (rDNA origin)
- Where
- Argentina
- Volunteers
- 110 people
- Sponsor
- Bio Sidus SA
Postmenopausal Osteoporosis
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
- Trial name
- NCT04366726
- Testing
- abaloparatide-sMTS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Radius Health, Inc.
Osteoporosis, Postmenopausal
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.
- Trial name
- NCT01457950
- Testing
- denosumab, open-label denosumab
- Where
- 10 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Bone Loss, Osteoporosis
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.
- Trial name
- NCT01159873
- Testing
- CEP-37251
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cephalon
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Study for Patients With Osteoporosis
The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis
- Trial name
- NCT00414973
- Testing
- Teriparatide, Salmon Calcitonin
- Where
- 5 sites in China
- Volunteers
- 364 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month.
- Trial name
- NCT00532077
- Testing
- rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
- Where
- 5 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis
This study will test the safety and efficacy of AAE581 in increasing Lumbar Spine bone mineral density (BMD) at 12 months, by Dexa-scan (DXA) in postmenopausal women with osteoporosis.
- Trial name
- NCT00100607
- Testing
- AAE581
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
This is an observational study to investigate the prevalence of osteoporotic fractures in post menopausal patients. Post menopausal patients who visit OS(orthopedic surgery) including GHs(general hospitals) and clinics will be…
- Trial name
- TOP (NCT01381588)
- Testing
- Fracture evaluation
- Where
- South Korea
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
The study will evaluate the both the efficacy of odanacatib on Bone Mineral Density (BMD) and the safety of odanacatib for postmenopausal osteoporosis in patients previously treated with alendronate.
- Trial name
- NCT00885170
- Testing
- Odanacatib, Vitamin D3, Calcium
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Postmenopausal Osteoporosis
A Study of Monthly Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00247273
- Testing
- risedronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 1,294 people
- Sponsor
- Warner Chilcott
Osteoporosis, Postmenopausal
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General…
- Trial name
- NCT05419427
- Testing
- Denosumab, Denosumab-Ref
- Where
- India
- Volunteers
- 552 people
- Sponsor
- Lambda Therapeutic Research Ltd.
Osteoporosis
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.
- Trial name
- NCT00170911
- Testing
- AAE581
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including…
- Trial name
- NCT05433207
- Testing
- Eldecalcitol soft capsules
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chugai Pharmaceutical